Get started
Author

Wujianhong Liu

ORCID: 0000-0001-8208-4348
Observed ORCID: 0000-0001-8208-4348
OpenAlex ID: A5079417307
Lipid metabolic reprogramming in colorectal cancer: mechanisms and therapeutic strategies
2025 · Wujianhong Liu, Shengrong Dong, et al. · Frontiers in Immunology · 21
PDF
Olaparib Combined with Abiraterone versus Olaparib Monotherapy for Patients with Metastatic Castration-resistant Prostate Cancer Progressing after Abiraterone and Harboring DNA Damage Repair Deficiency: A Multicenter Real-world Study
2024 · Jun Xie, Hanxu Guo, et al. · European Urology Oncology · 14
Comparison of combined MRI-TRUS fusion targeted and systematic biopsy vs systematic biopsy alone for the detection of prostate cancer in the Chinese biopsy-naïve patients: a prospective, single-center trial
2025 · Wujianhong Liu, Aimaitiaji Kadier, et al. · International Journal of Surgery · 4
Combined MRI-TRUS fusion targeted and systematic biopsy versus systematic biopsy alone for the detection of prostate cancer: protocol for a prospective single-centre trial
2024 · Wujianhong Liu, Aimaitiaji Kadier, et al. · BMJ Open · 3
Postoperative chemotherapy significantly improves survival of elderly patients with stage IB‐II non‐small cell lung cancer: A population‐based study
2023 · Wujianhong Liu, Shangshang Ma, et al. · Cancer Medicine · 3
PDF
Comparison of quantitative functional RAD51 foci and genomic alterations in predicting PARPi response in mCRPC: A multicenter real-world study.
2026 · Bin Yang, Hanxu Guo, et al. · Journal of Clinical Oncology
PDF
Supplementary Table S3 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
2025 · Ruiliang Wang, Jing Xu, et al.
Supplementary Table S2 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
2025 · Ruiliang Wang, Jing Xu, et al.
Supplementary Table S1 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
2025 · Ruiliang Wang, Jing Xu, et al.
Table 1 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
2025 · Ruiliang Wang, Jing Xu, et al.
Supplementary Table S5 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
2025 · Ruiliang Wang, Jing Xu, et al.
Supplementary Table S4 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
2025 · Ruiliang Wang, Jing Xu, et al.
Data from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
2025 · Ruiliang Wang, Jing Xu, et al.
Supplementary Figure S2 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
2025 · Ruiliang Wang, Jing Xu, et al.
Figure 1 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
2025 · Ruiliang Wang, Jing Xu, et al.
Supplementary Figure S4 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
2025 · Ruiliang Wang, Jing Xu, et al.
Figure 4 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
2025 · Ruiliang Wang, Jing Xu, et al.
Figure 6 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
2025 · Ruiliang Wang, Jing Xu, et al.
Figure 3 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
2025 · Ruiliang Wang, Jing Xu, et al.
Figure 2 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
2025 · Ruiliang Wang, Jing Xu, et al.
Supplementary Figure S3 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
2025 · Ruiliang Wang, Jing Xu, et al.
Figure 5 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
2025 · Ruiliang Wang, Jing Xu, et al.
Supplementary Figure S1 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
2025 · Ruiliang Wang, Jing Xu, et al.
Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study
2025 · Ruiliang Wang, Jing Xu, et al. · Cancer Research Communications
PDF
Re: Cathrine Alvær Vinje, Maria Nyre Vigmostad, Svein R. Kjosavik, Henrik Grönberg, Bjørnar Gilje, Svein Skeie. Prostate Biopsies Can Be Omitted in Most Patients with a Positive Stockholm3 Test and Negative Prostate Magnetic Resonance Imaging. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.08.009
2024 · Wujianhong Liu, Yanyan He, et al. · European Urology Focus
Works count: 25
Citation count: 45
H-index: 3
I10-index: 2
Year
Topic
Type